Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2025 | SUPRAME: a PRAME-specific TCR-T cell therapy in cutaneous melanoma

Jason Luke, MD, FACP, FASCO, UPMC Hillman Cancer Center, Pittsburgh, PA, gives an overview of the Phase III SUPRAME trial (NCT06743126), which evaluates the efficacy of IMA203, a PRAME-specific T cell receptor T cell therapy (TCR-T) cell therapy, in pretreated unresectable or metastatic cutaneous melanoma. This randomized study will be the first in solid tumors to assess a cellular therapy against investigator’s choice in patients and will assess progression-free survival as the primary endpoint. IMA203 has shown promising early results in melanoma and unlike tumor infiltrating lymphocytes, lower doses of interleukin-2 are needed. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.